Hepatology Journal
Overview
Publication venue for
- EPHA2 PROMOTES INFLAMMATION AND ALTERS HEPATOCYTE METABOLISM TO ENHANCE METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE. 80:S79-S79. 2024
- GAPS IN HEPATITIS B LABORATORY MONITORING AMONG AN ETHNICALLY DIVERSE COHORT OF ADULTS WITH TREATMENTNA& IUML; VE CHRONIC HEPATITIS B INFECTION IN THE UNITED STATES. 80:S166-S166. 2024
- GENDER- SPECIFIC DISPARITIES IN RECEIVING ANTIVIRAL THERAPY AMONG TREATMENT- ELIGIBLE ADULTS WITH CHRONIC HEPATITIS B INFECTION ACROSS THREE SAFETY- NET HEALTH SYSTEMS IN THE UNITED STATES. 80:S165-S166. 2024
- GENETIC AND PHARMACOLOGICAL TARGETING OF HEPATIC OXALATE OVERPRODUCTION AMELIORATES METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS. 80. 2024
- GLOBAL SOCIOECONOMIC DISPARITIES AFFECT ACUTE KIDNEY INJURY OUTCOMES IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: AN ANALYSIS OF THE INTERNATIONAL CLUB OF ASCITES GLOBAL AKI STUDY. 80:S1660-S1662. 2024
- PHENOTYPES, NATURAL COURSE, AND OUTCOMES OF ACUTE KIDNEY INJURY ( AKI) IN PATIENTS WITH ACUTE- ONCHRONIC LIVER FAILURE ( ACLF): RESULTS FROM THE ICA- GLOBAL AKI STUDY. 80:S128-S130. 2024
- A NOVEL HCC WAITLIST DROPOUT SCORE: BIOMARKER INTEGRATED DROPOUT GRADIENT ESTIMATION (BRIDGE). 78:S354-S354. 2023
- ALTERED EphA2 SIGNALING IN NON- ALCOHOLIC FATTY LIVER DISEASE PROGRESSION. 78:S1070-S1070. 2023
- EVALUATING PROVIDERLEVEL FACTORS CONTRIBUTING TO SUB-OPTIMAL SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA AMONG PATIENTS WITH CIRRHOSIS ACROSS FOUR SAFETY-NET HEALTH SYSTEMS IN THE UNITED STATES. 78:S1698-S1699. 2023
- NOVEL PATTERNS AND SURVIVAL EFFECTS OF RE-ABSTINENCE AFTER HARMFUL ALCOHOL USE FOLLOWING EARLY LIVER TRANSPLANT FOR SEVERE ALCOHOL-ASSOCIATED HEPATITIS: AN ACCELERATE STUDY. 78:S1629-S1631. 2023
- Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis. 77:E174-E175. 2023
- EX SITU END ISCHEMIC HYPOTHERMIC OXYGENATED PERFUSION (HOPE) VERSUS STATIC COLD STORAGE PRIOR TO LIVER TRANSPLANTATION EARLY RESULTS OF THE BRIDGE TO HOPE PIVOTAL MULTICENTER RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE SAFETY AND EFFECTIVENESS OF THE VITASMART LIVER MACHINE PERFUSION SYSTEM (CLINICALTRIALS.GOV: Nct05045794). 77:E124-E125. 2023
- ALTERED EphA2 SIGNALING IN NON-ALCOHOLIC FATTY LIVER DISEASE PROGRESSION. 76:S769-S770. 2022
- EXOSOME SHEDDING IS ASSOCIATED WITH TIME TO PROGRESSION IN NON-RESECTABLE, TRANSPLANT ELIGIBLE HCC UNDERGOING FIRST CYCLE LIVER-DIRECTED THERAPY.. 76:S179-S180. 2022
- HEPATOCELLULAR CARCINOMA SURVEILLANCE BIOMARKERS ALPHA-FETOPROTEIN-L3 AND DES-GAMMA-CARBOXY PROTHROMBIN IN THE CONTEXT OF CURRENT ALPHA-FETOPROTEIN BIOMARKER UTILIZATION IN BRIDGE TO LIVER TRANSPLANT. 76:S471-S471. 2022
- HEPATORENAL SYNDROME AND ACUTE TUBULAR NECROSIS IN CIRRHOSIS HAVE SIMILAR OUTCOMES: A MULTICENTER, ADJUDICATED CONSECUTIVE CASE SERIES FROM THE HRS-HARMONY COLLABORATIVE. 76:S1135-S1136. 2022
- REAL-WORLD SAFETY EXPERIENCE IN PATIENTS WITH ALAGILLE SYNDROME TREATED WITH MARALIXIBAT. 76:S1528-S1528. 2022
- USING THE PREDICTION INTERVAL TO APPLY CLINICAL TRIAL RESULTS AT THE LEVEL OF AN INDIVIDUAL PATIENT. 76:S683-S684. 2022
- A CASE SERIES OF SAFETY AND EFFICACY OF CRUSHED SOFOSBUVIR/VELPATASVIR IN HEPATITIS C INFECTED PATIENTS.. 74:583A-583A. 2021
- CHARACTERISTICS AND OUTCOMES OF SPLENIC INFARCTION IN PATIENTS WITH CIRRHOSIS: NIS DATABASE. 74:1207A-1207A. 2021
- GENE EXPRESSION OF TUMOR SIGNALING PATHWAYS IN EARLY STAGE NAIVE AND LIVER-DIRECTED THERAPY TREATED HEPATOCELLULAR CARCINOMA. 74:643A-644A. 2021
- ELEVATIONS IN PD-1 CORRELATES WITH LOCOREGIONAL TREATMENT RESPONSE AND BRIDGE TO TRANSPLANT SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS AWAITING LIVER TRANSPLANTATION. 72:694A-694A. 2020
- NOVEL QUALITY METRICS OF PSYCHOSOCIAL ASSESSMENT PREDICT HARMFUL ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION FOR ALCOHOL-ASSOCIATED HEPATITIS. 72:180A-180A. 2020
- SCREENING DIABETIC PATIENTS FOR NAFLD IS COST EFFECTIVE IN THE UNITED STATES: A COMPREHENSIVE ECONOMICAL ANALYSIS. 72:993-994. 2020
- T CELL REPERTOIRE DIVERSITY IN HCV-ASSOCIATED HEPATOCELLULAR CARCINOMA PATIENTS FOLLOWING LOCOREGIONAL THERAPY WHILE WAITLISTED FOR LIVER TRANSPLANTATION. 72:709A-710A. 2020
- WAYS TO ESTIMATE BENEFITS OF TREATMENT FOR NONALCOHOLIC STEATOHEPATITIS IN AN INDIVIDUAL PATIENT. 72:1042-1042. 2020
- ELEVATIONS IN PD-1 CORRELATES WITH LOCOREGIONAL TREATMENT RESPONSE AND BRIDGE TO TRANSPLANT SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS AWAITING LIVER TRANSPLANTATION. 72:694A-694A. 2020
- NOVEL QUALITY METRICS OF PSYCHOSOCIAL ASSESSMENT PREDICT HARMFUL ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION FOR ALCOHOL-ASSOCIATED HEPATITIS. 72:180A-180A. 2020
- SCREENING DIABETIC PATIENTS FOR NAFLD IS COST EFFECTIVE IN THE UNITED STATES: A COMPREHENSIVE ECONOMICAL ANALYSIS. 72:993-994. 2020
- T CELL REPERTOIRE DIVERSITY IN HCV-ASSOCIATED HEPATOCELLULAR CARCINOMA PATIENTS FOLLOWING LOCOREGIONAL THERAPY WHILE WAITLISTED FOR LIVER TRANSPLANTATION. 72:709A-710A. 2020
- WAYS TO ESTIMATE BENEFITS OF TREATMENT FOR NONALCOHOLIC STEATOHEPATITIS IN AN INDIVIDUAL PATIENT. 72:1042-1042. 2020
- A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS. 70:43A-44A. 2019
- DONOR SPECIFIC ANTIBODY IN SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION: PREFORMED CLASS II HLA ANTIBODIES AND ACUTE RENAL AND HEPATIC ALLOGRAFT REJECTION. 70:706A-706A. 2019
- Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?. 69:51-63. 2019
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. 70:1521-1530. 2019
- PATTERNS OF ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION (LT) FOR ALCOHOLIC HEPATITIS (AH): IMPLICATIONS FOR SELECTION AND MONITORING. 70:3A-4A. 2019
- PRE-TREATMENT LYMPHOCYTE STATUS IN HCC PATIENTS ASSOCIATES WITH DEB-TACE RESPONSE AND CORRELATES WITH LIVER SYNTHETIC DYSFUNCTION AND INCREASED REGULATORY IMMUNE CELLS. 70:527A-528A. 2019
- Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. 69:1477-1487. 2019
- Eight Week Hepatitis C Treatment with New Direct Acting Agents Have a Better Safety Profile While Effective in the Geriatric Population without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/Ml. 68:413A-414A. 2018
- Hyperbilirubinemia Promotes Alterations in T Cell Function and Induces Immunotolerogenic Immune Cells in a Mouse Model. 68:940A-941A. 2018
- Modeling Long-Term Outcomes of Early Liver Transplantation (ELT) Vs. Delayed LT (6-Month Wait) for Severe Alcoholic Hepatitis (AH) and Quantifying the Impact of Harmful Alcohol Use Post-LT. 68:656A-656A. 2018
- Necroptosis Contributes to Cell Death of Steatotic Hepatocytes Following Ischaemic Injury. 68:687A-687A. 2018
- Novel Predictors of Alcohol Use after Early Liver Transplantation (LT) for Severe Alcohol-Associated Hepatitis (AAH) and Impact on Long-Term (5-Year) Survival. 68:100A-100A. 2018
- Pre-Transplant Corticosteroids (CS) and Infection Risk after Early Liver Transplantation (LT) for Severe Alcoholic Hepatitis (AH): Good or Bad?. 68:681A-681A. 2018
- Predicting Low-Risk for Sustained Alcohol Use after Early Liver Transplant for Severe Alcoholic Hepatitis: The Salt Score. 68:8A-8A. 2018
- The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis B Mothers. A Clinical Perspective Reply. 68:1658-1660. 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. 67:1560-1599. 2018
- Clinical Predictors of Biliary Obstruction at ERCP After Orthotopic Liver Transplantation (OLT). 66:921A-921A. 2017
- High Cure Rate of Hepatitis C in a Primary Care Clinic for People Who Have Limited Access to Specialty Care. 66:845A-845A. 2017
- IL-33/Cyclin D1 Imbalance in Severe Liver Steatosis Predicts Susceptibility to Ischemia Reperfusion Injury in Rats.. 66:1097A-1097A. 2017
- Liver Disease Management TeleECHO Improves Provider Knowledge and Care of Patients. 66:314A-314A. 2017
- Lymphopenia in Waitlist Treatment Naive HCC Patients is Associated with Increased Myeloid-Derived Suppressor Cell Expansion and Decreased Tumor Response to Doxorubicin-Eluting Bead Transarterial Chemoembolization. 66:382A-382A. 2017
- Post-Transplant Outcomes from the Multi-Center American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) Study. 66:17A-17A. 2017
- AASLD guidelines for treatment of chronic hepatitis B. 63:261-283. 2016
- Clearance of the hepatitis C virus without treatment occurs more often than traditionally reported. 64:394A-395A. 2016
- Liver Transplantation for "Very Early" Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment. 64:1178-1188. 2016
- The Expression of RIP3 and IL-33 in Severely Steatotic Rat Livers Correlates with Susceptibility to Liver Failure Following Ischemia Reperfusion Injury.. 64:342A-342A. 2016
- Pre-treatment with TIMP-3 prevents the development of biliary injury in an LPS enhanced ischaemia-reperfusion animal model. 62:616A-616A. 2015
- Prevention of Recurrent Hepatitis C in Liver Transplant (LT) Recipients with Civacir (R) : Preliminary Results on Safety and Efficacy, Including Patients with Renal/Liver Dysfunction. 62:310A-310A. 2015
- Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study. 62:1387A-1388A. 2015
- The Association of Pre-Transplant Sarcopenia and Cirrhotic Cardiomyopathy with Postoperative Complications after Liver Transplant.. 62:824A-824A. 2015
- Clinical Outcomes of Hepatitis B Virus Coinfection in a United States Cohort of Hepatitis C Virus-Infected Patients. 60:1871-1878. 2014
- High efficacy and favorable safety profile of Daclatasvir based all oral antiviral therapy in liver Transplant recipients with severe recurrent HCV. 60:1280A-1281A. 2014
- Impaired expression of Type I and Type II interferon-receptors in HCV infected chronic liver disease and liver cirrhosis. 60:1084A-1084A. 2014
- Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin. 60:542A-543A. 2014
- Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT). 60:206A-207A. 2014
- Shear Wave Elastography and Hepatorenal Index for the Assessment of Liver Fibrosis and Steatosis: a Novel technique and its Predictive Accuracy and Optimal Measurement Location. 60:445A-446A. 2014
- ALT Flares Are Infrequent During the Course of Pregnancy: Prospective Study from the Hepatitis B Research Network (HBRN) Adult Cohort Study. 58:646A-647A. 2013
- Liver transplantation in the morbidly obese: Do the outcomes justify the use of scarce organs?. 58:1031A-1031A. 2013
- EMERGENCE OF YMDD LAMIVUDINE RESISTANCE AFTER TRANSPLANTATION OF ANTI-HBC POSITIVE DONOR LIVERS INTO ANTI-HBC NEGATIVE RECIPIENTS USING LAMIVUDINE MONOTHERAPY PROPHYLAXIS. 54:631A-631A. 2011
- IMPAIRED JAK-STAT SIGNALING OF INTERFERON-alpha IN CHRONICALLY HCV INFECTED LIVER TISSUE. 52:746A-746A. 2010
- LIVER TRANSPLANTATION IN THE SUPER MORBIDLY OBESE: A SINGLE CENTER EXPERIENCE; SECTION OF ABDOMINAL TRANSPLANTATION, OCHSNER CLINIC FOUNDATION, NEW ORLEANS, LA. 50:584A-585A. 2009
- SPLIT RENAL FUNCTION SCANNING DEMONSTRATES LIMITED RECOVERY OF NATIVE RENAL FUNCTION ONE YEAR AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION IN RECIPIENTS WHO WERE NOT DIALYSIS DEPENDANT. 50:559A-559A. 2009
- SPLIT RENAL FUNCTION SCANNING DEMONSTRATES LIMITED RECOVERY OF NATIVE RENAL FUNCTION ONE YEAR AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION. 48:337A-337A. 2008
- TISSUE INHIBITOR OF METALLOPROTEINASE-3 (TIMP-3) PROTECTS LIVER HISTOLOGY AND BIOCHEMISTRY IN RATS UNDERGOING SUB-LETHAL TOTAL HEPATIC ISCHEMIA. 48:995A-996A. 2008
Identity
International Standard Serial Number (ISSN)
- 0270-9139